Health · Medical Research · 3 hrs ago

Malaria antibody protected infants but weakened vaccine response in study

Malaria antibody protected infants but weakened vaccine response in study

Researchers tested the L9LS malaria antibody in infants in Mali and found it protected them against malaria over a six-month transmission season.

The antibody was 78% effective compared with a placebo, but it also reduced antibody levels from the R21 vaccine by 20% to 30%.

It is not yet clear whether that lower response in blood tests means the vaccine would provide less protection in everyday life.

Malaria vaccines require multiple doses, with the first given at five months of age, while one antibody shot may protect for several months.

Malaria killed about 610,000 people in 2024, most of them children under five in sub-Saharan Africa.

The results raise questions about giving L9LS and R21 to infants together, even though the antibody could offer another way to protect children during malaria season.

Researchers plan to focus pivotal studies on groups other than babies and hope to start those studies in 2028.

1 source

Related

What people are saying

Robert SederNational Institute of Allergy and Infectious Diseases researcher
We have these other clear use cases, so let’s get those done and get it approved and we can come back and revisit this
via STAT
Kassoum KayentaoUniversity of Sciences, Techniques, and Technologies of Bamako expert involved in the research
A monoclonal antibody, with only one shot, provides an efficacy over six months, and those six months correspond to the season of malaria in Sahelian regions.
via STAT
In terms of logistics, in terms of programmatical use, this could be a very good tool.
via STAT